CRST Helsinki Oy
- Address
- lock Available on a paid plan
Diagnosis and Analytical Techniques
The Helsinki site advances diagnostic accuracy by testing innovative imaging and pharmacokinetic methods across several conditions.
- Evaluation of CT imaging for detecting activated brown fat in healthy volunteers
- Pharmacokinetic profiling of a novel agent in Parkinson's disease patients
- Biomarker assessment in primary sclerosing cholangitis to improve disease monitoring
Research conducted at CRST Helsinki Oy supports more precise diagnosis and patient stratification.
Cardiovascular Disease Research
Clinical programs focus on reducing heart‑related events in individuals with metabolic risk factors.
- Testing a dual therapy of vicadrostat and empagliflozin to lower cardiovascular mortality
- Monitoring blood pressure outcomes in participants with hypertension
- Evaluating time to first heart failure hospitalization in patients with established cardiovascular disease
The trials at this Finnish location aim to improve long‑term heart health for high‑risk groups.
Digestive System Disease Studies
Investigations target gut‑related disorders, emphasizing dietary challenges and liver‑bile duct health.
- Reducing gluten‑induced damage in celiac disease through targeted antibodies
- Promoting mucosal healing in non‑responsive celiac disease patients
- Characterizing drug exposure in individuals with primary sclerosing cholangitis
Work conducted by CRST Helsinki Oy seeks to enhance quality of life for those with chronic digestive conditions.
Immune‑Mediated Disease Research
Studies explore how modulating immune pathways can alleviate symptoms of skin and gut inflammation.
- Assessing pruritus relief in prurigo nodularis with a novel biologic
- Investigating immune signaling inhibition for chronic skin inflammation
- Evaluating autoimmune components of celiac disease under controlled exposure
The Helsinki team at CRST Helsinki Oy contributes to new therapeutic options for immune‑driven disorders.
Neurological Disorder Trials
The portfolio includes multiple studies aimed at preserving cognition and safety in neurodegenerative diseases.
- Measuring cognitive change in early Alzheimer's disease using novel agents
- Testing treatment impact on mild to moderate Alzheimer's disease progression
- Conducting safety assessments of a new compound in patients with Parkinson's disease
Efforts by CRST Helsinki Oy aim to slow disease advancement and improve daily functioning.
Dermatology and Connective Tissue Research
Focused on chronic skin conditions, the trials evaluate symptom relief and patient‑reported outcomes.
- Reducing itch intensity in prurigo nodularis through targeted therapy
- Enhancing skin barrier integrity in persistent dermatologic disease
- Tracking quality‑of‑life improvements in long‑standing skin disorders
The work at CRST Helsinki Oy supports better management strategies for affected individuals.
Psychiatry and Mental Health Studies
Research addresses cognitive impairment and mental health outcomes in early dementia and related conditions.
- Improving thinking skills in patients with early Alzheimer's disease
- Monitoring neuropsychiatric symptoms in mild cognitive impairment cohorts
- Evaluating mental function alongside daily living abilities in dementia research
Contributions from CRST Helsinki Oy strive to enhance therapeutic options for mental disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 16 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Boehringer Ingelheim Espana S.A.1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CRST Helsinki Oy
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 2B, multicenter, randomized, double-blind, placebo-controlled, dose-finding, efficacy and safety study of HRO350 in subjects with mild-to-moderate psoriasis (the ‘HeROPA’ study) | Arctic Bioscience AS | Phase II | Not Recruiting | Mar 2023 | Mar 2025 |
IMP list
lock Showing 1 of 16 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rocatinlimab | 3 | Unknown | 2023-04-25 | 2024-11-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.